We investigated αVβ6-dependent adhesion signaling complexes and identified an αVβ6/HER2 cross-talk mechanism, which drives invasion and is dysregulated in trastuzumab-resistant HER2+ breast cancer cells. Here, ERBB2 is linked to breast carcinoma.